Global Antiviral Drugs Market by Application (HIV, Influenza, Hepatitis, Herpes), by Type (Generics, Branded) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028

Summary of the Report

Global antiviral drug market was worth USD 62.8 billion in 2020. It is projected to grow at a compound annual rate (CAGR of -0.6%) between 2021 and 2028. The growth of the market is being affected by the introduction of generic antiviral medications and increasing awareness about the availability vaccines against viral infections.

However, antiviral medications will be more in demand due to the rising prevalence of viral diseases such as HIV, Herpes and Influenza over the forecast period. UNAIDS estimates that more than 37 million people worldwide were living with HIV in 2020. In 2020, 1.5 million people contracted HIV from these individuals. The overall impact of the COVID-19 pandemic on market growth has been significant in 2020, while a negative effect has been seen for antiviral drug applications.

The rising incidence of viral infections around the world is a key factor in driving demand for antiviral medications over the forecast period. WHO estimates that 325 million people worldwide have hepatitis C virus. Of these, 71 million are suffering from chronic hepatitis C virus infections. The U.S. Department of Health and Human Services estimates that approximately 2.4 million Americans have hepatitis C and 850,000 people in the United States have hepatitis B. Global demand for antiviral medications will rise due to an increasing number of patients.

Market growth is expected to be driven by the increasing approval and anticipated commercialization of novel medicines against viral infections. In November 2020, for example, the U.S. FDA approved a supplemental New Drug Application (SNDA) for Roche's Xofluza to treat influenza in patients aged 12 and over. In addition, major market players have developed many new medicines within 2 to 3 years of each other for the treatment and prevention of viral infections. Gilead Sciences, Inc., for the treatment and prevention of viral infections, has released Symtuza, Biktarvy, and Veklury. GlaxoSmithKline plc. Dovato, Cabenuva and Juluca have been launched to treat diseases caused by the virus. Growth will be driven by the increased introduction of new products to the market over the next 2-3 years.

Global demand for antiviral medications has increased significantly since the COVID-19 pandemic. Broad-spectrum antiviral medications are needed to treat novel coronavirus. For COVID-19, the most prescribed combination medicines include remdesivir and favipiravir. Governments are providing more funding for pharmaceutical companies in order to develop new therapies against COVID-19. In June 2021, for example, the U.S. government announced a more than USD 3Billion investment to accelerate the development, discovery and manufacture of antiviral medications for COVID-19 treatment. In the next 2 to 3-years, antiviral drugs will be in high demand due to rising disease incidence and increased R&D.

In the next few years, there will be a lot of new drugs developed through increased collaborations in the production and development of antiviral medications. To reduce the burden of viral infection treatment, the key players are working together. To increase the supply of remdesivir, Gilead Sciences, Inc. signed a licensing agreement in 2020 with pharmaceutical companies such as Cipla Ltd., Hetero Laboratories Ltd., Dr. Reddy's Laboratories Ltd., Mylan, etc.

Drug Class Insights

In 2020, the reverse transcriptase inhibitors market dominated antiviral drug markets and was responsible for 49.0% of the total revenue. It is expected to continue its dominance in the future. This high proportion of reverse transcriptase inhibits can be attributed both to an increasing diagnosis and treatment rate for HIV and to the high effectiveness of these drugs in fighting viral infections. In the future, there will be a lot of demand for reverse transcriptase inhibitors due to the fact that they are already in production. This drug class includes Nucleoside Transcriptase Inhibitors and Non-nucleoside Transcriptase Inhibitors.

Protease inhibitors segment had the second-largest revenue share for 2020. It is expected to see a CAGR in the forecast period of -1.4%. The decrease in segment growth can be attributed both to increased vaccination against viral infections as well as reduced R&D activities for the development of protease inhibits.

Type Insights

Branded segment was the dominant market player and had a 57.2% revenue share in 2020. This segment is expected to continue its dominance during the forecast period. A significant portion of the market is held by antiviral brands such as Biktarvy and Genvoya, Triumeq and Mavyret. This segment is expected to be driven by the high adoption rate for branded drugs in North America and Europe, as well as the high price of drugs.

The generics segment is seeing a rise in demand for generic antiviral medications in developing countries because of its affordability. Generic antiviral drugs are highly competitive and cost-sensitive. Generic antiviral drugs are highly competitive because of the presence of many generic pharmaceutical manufacturers like Cipla Inc. and Aurobindo Pharma.

Application Insights

The market was dominated by the HIV segment, which held 44.1% of the total revenue in 2020. This segment is expected to grow at the fastest rate during the forecast period. Market growth is expected to be driven by the high prevalence of HIV infection, high treatment rates, availability of brand drugs, and government initiatives to improve the treatment rate. In 2019, the United States government announced the Ending The HIV Epidemic (EHE), plan to eliminate the HIV epidemic by 2030. This initiative aims to reduce HIV infection and increase the rate of diagnosis and treatment in the U.S. Market growth will be fueled by strong pipeline drugs to treat HIV infection over the forecast period.

In 2020, the hepatitis segment accounted for the second largest revenue share. The growth is being adversely affected by the increased vaccination against hepatitis A/B. The COVID-19 pandemic in 2020 has also significantly impacted the growth of other segments. COVID-19 has seen the other segment share increase from 6.3% to 23.5% between 2019 and 2020.

Regional Insights

North America was the dominant market, accounting for the largest revenue share in 2020. Over the forecast period, North America is expected to experience a CAGR in excess of 1.8%. Market decline can be attributed primarily to declining market exclusivity for branded drugs, rising vaccination rates against viral infections and government initiatives to lower the incidence of viral infection. The U.S. government has taken various steps to promote R&D and investment in innovative treatments for viral infections.

The fastest growing market for antiviral medications in Asia Pacific is expected to be during the forecast period. This market's high growth can be attributed to increasing viral infection rates and the development of healthcare infrastructure in the region. It also reflects the growing awareness of infectious diseases and the rising prevalence of viral infections. The strong presence of generic pharmaceutical manufacturing firms in India, China and other South Asian nations, as well as the growing geriatric population of the region, are key factors that have contributed to the segment's growth.

Market Share Insights & Key Companies

Many generic pharmaceutical companies are involved with the production and distribution of antiviral medications, making it highly competitive in the global market. Gilead Sciences, Inc., and GlaxoSmithKline plc are the main players in this market. These companies held a large market share in 2020, and they also have potential pipeline drugs that will be commercialized during the forecast period. The following are some of the most prominent players in antiviral drug market:

• F. Hoffmann-La Roche Ltd.

• GlaxoSmithKline plc

• AbbVie

• Merck & Co., Inc.

• Johnson & Johnson Services, Inc.

• Bristol-Myers Squibb Company

• Cipla Inc.

• Aurobindo Pharma

• Dr. Reddy's Laboratories Ltd.

Up Market Research published a new report titled “Antiviral Drugs Market research report which is segmented by Application (HIV, Influenza, Hepatitis, Herpes), by Type (Generics, Branded), By Players/Companies AbbVie, Merck & Co Inc, Johnson & Johnson Services Inc, Dr Reddy’s Laboratories Ltd, Bristol-Myers Squibb Company, Aurobindo Pharma, F Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Cipla Inc”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.

Report Scope

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.

Global Antiviral Drugs Market Report Segments:

The market is segmented by Application (HIV, Influenza, Hepatitis, Herpes), by Type (Generics, Branded).

Some of the companies that are profiled in this report are:

1. AbbVie
2. Merck & Co Inc
3. Johnson & Johnson Services Inc
4. Dr Reddy’s Laboratories Ltd
5. Bristol-Myers Squibb Company
6. Aurobindo Pharma
7. F Hoffmann-La Roche Ltd
8. GlaxoSmithKline plc
9. Cipla Inc

Antiviral Drugs Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.

Key Benefits for Industry Participants & Stakeholders:

• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Antiviral Drugs Market

Overview of the regional outlook of the Antiviral Drugs Market:

Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.

Highlights of The Antiviral Drugs Market Report:

1. The market structure and projections for the coming years.
2. Drivers, restraints, opportunities, and current trends of Antiviral Drugs Market.
3. Historical data and forecast.
4. Estimations for the forecast period 2028.
5. Developments and trends in the market.

                1. HIV

                2. Influenza

                3. Hepatitis

                4. Herpes

                1. Generics

                2. Branded

8. Market scenario by region, sub-region, and country.
9. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
10. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
11. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Antiviral Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.

How you may use our products:

• Correctly Positioning New Products
• Market Entry Strategies
• Business Expansion Strategies
• Consumer Insights
• Understanding Competition Scenario
• Product & Brand Management
• Channel & Customer Management
• Identifying Appropriate Advertising Appeals

Reasons to Purchase the Antiviral Drugs Market Report:

• The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
• Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
• Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
• The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
• Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.